Scholarlink

<p>Synthetic lethality (SL) is a genetic interaction phenomenon in which a cell can survive when either of two genes is individually mutated, but simultaneous disruption of both genes leads to cell death. This phenomenon reveals the redundancy and complementarity among gene functions and provides a theoretical basis for precision cancer therapies targeting specific genetic defects. The SL approach achieves the selective elimination of cancer cells by targeting the synergistic survival pathways on which tumor-specific genetic defects rely. This review highlights the core molecular mechanisms of SL in DNA damage repair, cell cycle checkpoint regulation, metabolic reprogramming, and epigenetic regulation; summarizes target discovery strategies based on high-throughput functional genomics and computational biology; and discusses successful clinical translation cases exemplified by poly(ADP-ribose) polymerase (PARP) inhibitors, along with current challenges and future directions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Synthetic lethality in cancer: mechanism exploration and therapeutic applications

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月7日

查看全文
  • Pusong Zhao,
  • Peng Wang,
  • Tianqi Xu,
  • Ligang Chen,
  • Qingge Jia,
  • Mingyang Li

摘要

Synthetic lethality (SL) is a genetic interaction phenomenon in which a cell can survive when either of two genes is individually mutated, but simultaneous disruption of both genes leads to cell death. This phenomenon reveals the redundancy and complementarity among gene functions and provides a theoretical basis for precision cancer therapies targeting specific genetic defects. The SL approach achieves the selective elimination of cancer cells by targeting the synergistic survival pathways on which tumor-specific genetic defects rely. This review highlights the core molecular mechanisms of SL in DNA damage repair, cell cycle checkpoint regulation, metabolic reprogramming, and epigenetic regulation; summarizes target discovery strategies based on high-throughput functional genomics and computational biology; and discusses successful clinical translation cases exemplified by poly(ADP-ribose) polymerase (PARP) inhibitors, along with current challenges and future directions.